4% of survey complete.

Takeda values your honest opinions. Your data will be anonymous, and no individual responses will be shared. We are interested in learning about how to better support people with ALK+NSCLC (Non-Small Cell Lung Cancer).
The survey should take approximately 10 minutes.
Indication for ALUNBRIG® (brigatinib)
ALUNBRIG is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that have a certain abnormal anaplastic lymphoma kinase (ALK) gene that has spread to other parts of their body, and who have taken the medicine crizotinib, but their NSCLC worsened or they cannot tolerate taking crizotinib. It is not known if ALUNBRIG is safe and effective in children.

Please see Important Safety Information at the end of the Survey and full Prescribing Information.